News PTC Therapeutics fails to convince FDA panel about DMD drug FDA advisers have voted against approval for PTC Therapeutics’ Duchenne drug Translarna because of doubts about its efficacy.
News FDA reviewers slam PTC's Duchenne drug ahead of meeting FDA staff not persuaded by patchy clinical trial evidence for Translarna.
News Sarepta announces Allergan veteran as next CEO Sarepta has announced former Allergan president Doug Ingram will be its new CEO.
News UK patients gain early access to Duchenne drug Patients to get Santhera's Raxone under EAMS scheme.
News Outrage over Duchenne drug price reinflamed by PTC's $35,000... Families affected by the rare muscle wasting disease Duchenne muscular dystrophy will still have to pay a huge premium for Emflaza, a newly-approved drug based on an old steroid that helps
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.